-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.
Latest Posts
Podcast with Debra Miller, Cure Duchenne
Biotech-Now’s Tracy Krughoff spoke with Cure Duchenne’s President, Debra Miller. Cure Duchenne will be one of the patient advocacy organizations presenting at the Eighth Annual BIO Investor Forum next week. Listen Now!
Novavax launches study of novel H1N1 vaccine in Mexico
Novavax, Inc. (Nasdaq: NVAX) initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to distribute the H1N1 VLP vaccine in Mexico in 2010 if it is approved for commercial sale. In Read More >
Clinical trial results for Calistoga Pharmaceuticals’ CAL-101
Calistoga Pharmaceuticals, Inc., announced interim results from the ongoing Phase 1 trial evaluating CAL-101, a PI3K inhibitor, showing promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At this interim assessment, 29 percent of CLL patients treated in the cohort expansion dose levels had partial responses observed after 28 days of therapy (1 cycle) and 94 percent have achieved evidence of biologic activity with a greater than 50 percent decrease in Read More >
Endocyte announces close of $26 million equity financing
Endocyte, Inc., completed a $26 million extension of its Series C financing. This round included participation from all existing institutional investors including Sanderling Ventures, Burrill & Company, American Bailey Ventures, Blue Chip Venture Company, and Triathlon Medical Ventures. Clarian Health Ventures also participated as a new investor.
Targacept reports positive Phase 2b trial results for depression treatment
Targacept, Inc. (NASDAQ: TRGT) presented data from its Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide. In the trial, the add-on TC-5214 arm (TC-5214 + citalopram) outperformed the add-on placebo arm (placebo + citalopram) on the primary outcome measure, the Hamilton Rating Scale for Depression-17, or HAM-D, and all of the secondary Read More >
